Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Non-small Cell Lung Cancer Metastatic 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Meningioma 1Melanoma 1Lymphoma 1Fallopian Tube Neoplasms 1Exanthema 1Endometrial Neoplasms 1Disease Progression 1Diarrhea 1Chondrosarcoma 1Carcinoma, Squamous Cell 1CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1Advanced Gastric Cancer 1Advanced Cancer 1Advanced Breast Cancer 1

Interventions

capivasertib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × CCCA Assessed by Ki67 Drop Below <2.7% From Baseline × capivasertib × Clear all
NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

GBG Forschungs GmbH

Phase 2 Recruiting
120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Data powered by HemOnc (CC BY 4.0) Colophon âš¡